Kronos Bio (NASDAQ: KRON)
Some price data may be temporarily unavailable.
Kronos Bio Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Kronos Bio Company Info
Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.
News & Analysis
No articles found.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.